Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-GD2-800CW Imaging in Pediatric Neuroblastoma
NCT07399821Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Nov 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Anti-GD2-800CW in neuroblastoma, sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Recommended Phase 2 Dose at 1 year and Adverse Events. Started Nov 2025; status: recruiting.
02
Drugs
Anti-GD2-800CW
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07399821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399821.